First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
05. Juni 2024 08:30 ET
|
Imunon, Inc.
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company...
NEXGEL Reports Positive Results from Proof-of-Concept Study for its Diclofenac Hydrogel Pain Treatment
25. Oktober 2022 08:00 ET
|
NEXGEL, INC.
LANGHORNE, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for...